Uh, you see this photograph? I think there is nobody in this hall who must not have had a relative or somebody he knows who has not suffered from obesity. The problem of being overweight either some of your relatives would have suffered it or you yourself would have. And the problem with obesity is that there is just not the weight of the body there is also that weight of the shame. But guess this is the surprise. I never wanted to treat obesity in my life. Never. In fact, all I wanted to be is to become th ...

All right, welcome back everybody. CNBC has learned that healthcare industry leaders have sent a letter to President Trump to the Health and Human Services Secretary Robert F. Kennedy Jr.. and the head of the FD FDA, Dr. . Marty McCary. The leaders who are speaking up here are lod lodging some frustration with the FDA when it comes to approvals of potentially life-saving therapeutics for rare diseases.The group of U letter signitories are made up of biotech leaders, patient advocates, and academics who work ...

Group 1 - Teleflex Incorporated will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 10:00 a.m. GMT [1] - A live audio webcast of the presentation will be accessible on the investor section of the Teleflex website [1] Group 2 - Teleflex is a global provider of medical technologies focused on improving health and quality of life [2] - The company aims to be the most trusted partner in healthcare, offering a diverse portfolio in various therapy areas including anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology [2] - Teleflex believes in the potential of people, purpose-driven innovation, and world-class products to shape the future of healthcare [2] Group 3 - Teleflex is home to several trusted brands including Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™, and Weck™, all united by a common purpose [3] - The company emphasizes its commitment to empowering the future of healthcare [3]

Core Insights - The Chelsea Clinic has relocated to a larger, purpose-built facility at Ngee Ann City, enhancing its patient experience and reinforcing Singapore's status as an aesthetic medicine hub [1][2][4] - The new flagship facility integrates the medical clinic, spa, and corporate headquarters, featuring 16 rooms, including 12 clinic rooms and 4 spa rooms, designed for privacy and comfort [2][4] - The clinic has strengthened its Japanese-language support and communication channels to better serve the Japanese expatriate community and international patients [2][4] Company Overview - Founded in 1999 by Dr. Ewen Chee, The Chelsea Clinic is a pioneer in aesthetic medicine in Singapore, known for medically supervised aesthetic procedures [2][8] - The clinic is part of Aesthetic Healthcare Holdings (AHH) and SBC Medical Group, which operates a diverse range of medical and aesthetic services [9][10] - SBC Medical Group was listed on Nasdaq in September 2024 and included in the Russell 3000® Index in June 2025, indicating its growing presence in the medical field [10][11] Facility Features - The new facility includes dedicated consultation rooms for each doctor and expanded waiting lounges, creating a more personalized environment for patients [2][4] - Treatment rooms are named after Japanese cities, reflecting the clinic's connection to Japan and its parent company, SBC Medical [2][4] - The relocation aims to provide a more seamless and elevated patient journey, emphasizing comfort, privacy, and efficiency [4]

Core Viewpoint - Incyte Corporation is experiencing strong financial performance driven by its flagship product, Jakafi, despite a price target set by RBC Capital indicating potential downside for the stock [2][5]. Financial Performance - Incyte reported earnings of $2.26 per share for Q3 2025, surpassing the Zacks Consensus Estimate of $1.66 per share, resulting in an earnings surprise of 36.14% [2]. - The company's revenue for Q3 2025 was $1.37 billion, exceeding the Zacks Consensus Estimate by 8.71% and increasing from $1.14 billion in the same period last year [3]. - Incyte has consistently outperformed revenue expectations over the past four quarters, with strong demand for Jakafi being a key growth driver [3]. Stock Performance - The current stock price for Incyte is $89.66, reflecting a decrease of 2.17% with a trading range between $88.34 and $94.42 for the day [4]. - Over the past year, the stock has reached a high of $94.42 and a low of $53.56, with a market capitalization of approximately $17.5 billion [4][5]. - RBC Capital has set a price target of $84 for Incyte, suggesting a potential downside of approximately -8.35% from the current trading price [2].

Do ta filloj prezantimin në vitin e largët 1989 kur unë jetoja me familjen time bashkë në Bulqizë dhe ë lodra ime e parë, dhurata e parë që më bëhet ë është mundësia për të pasur një karrocë prej këtyre që ishin karrocën në kushinetën në atë kohë ë pata mundësinë që ta ndërtoj bashkë me babain tim dhe me shokët e tij, pasi ai kishte një dyqan, një ë ë magazinë ku shiste pjesë këmbimi. Ishin të shtetit normalisht, pasi në atë kohë nuk kishte dyqane private. Ë u aposionova shumë mbas kësaj pasi ishte ndërtuar ...

Core Insights - The seventh Health China-Sinan Dialogue focused on biomedicine innovation and international cooperation, gathering representatives from various sectors to explore new paths for industry development [1][4] - The Huangpu District aims to strengthen the Guangci-Sinan Park's platform functions, establishing a modern industrial system centered on digital technology and life health [1][5] Group 1: Key Initiatives and Collaborations - Eight major announcements and signing ceremonies were held, covering ecological construction, talent assurance, and technological innovation [2] - The Guangci-Sinan (Zhongganghui) Medical Transformation Innovation Ecosystem was launched in collaboration with Ruijin Hospital, marking a significant step in Shanghai's talent retention policies [2] - The establishment of a "Medical Device and Biotechnology Verification Center" in partnership with Weigao Medical and Noripharma aims to create a collaborative innovation mechanism driven by clinical needs [2] Group 2: Technological Advancements - The "AI + Digital Health Technology Pilot Platform" was introduced, focusing on AI applications in science, medicine, and health, leveraging a reliable medical model [2] - A "Tumor Diagnosis and Treatment Innovation Incubator" was signed, attracting multiple biopharmaceutical companies to enhance the park's industrial ecosystem [2] Group 3: Industry Growth and Future Plans - The Guangci-Sinan Park has attracted approximately 283 companies with a total registered capital of about 2.9 billion, becoming a key platform for the efficient integration of innovative elements [5] - Future plans include leveraging the Huangpu District's "Central Science and Technology Innovation Zone" strategy to support the biomedical industry's innovation and transformation [5]

Core Viewpoint - Guerbet has appointed Mr. Jérôme Estampes as interim Chief Executive Officer, succeeding Mr. David Hale, who is leaving the company to pursue new projects [2][3]. Company Management Changes - Mr. Jérôme Estampes has been with Guerbet since 2019 as Chief Administrative and Financial Officer, where he has developed a strong understanding of the company's financial, operational, and commercial challenges [3]. - The Board of Directors has expressed gratitude to Mr. David Hale for his contributions since joining in February 2018, first as Chief Commercial Officer and then as CEO from January 1, 2020 [2][4]. Transition and Future Leadership - The Board supports Mr. Estampes and he will have the assistance of Guerbet's Executive Committee to ensure a smooth transition and to continue implementing transformation measures and the commercial strategy [4]. - The Nominations and Remuneration Committee has initiated the recruitment process for a permanent Chief Executive Officer [4]. Company Overview - Guerbet is a global leader in medical imaging, focusing on improving patient care through innovation, with nearly a century of expertise [6]. - The company offers a comprehensive portfolio of pharmaceutical products, medical devices, and AI-driven solutions for diagnostic and interventional imaging [6]. - Guerbet invests 10% of its annual revenue in research and development and reported €786 million in revenue in 2023 [6].

Company Leadership - Penumbra, Inc. has announced the promotion of Shruthi Narayan to President, effective September 1, 2025, while Adam Elsesser continues as chairman and CEO [1] - Shruthi Narayan is recognized as a dynamic leader with a strong background in innovation and team inspiration, which is expected to support Penumbra's growth and market leadership [2] Professional Background - Ms. Narayan has 20 years of experience in the medical device industry, previously serving as president of Penumbra's interventional business, overseeing growth initiatives in neuro and vascular franchises [2] - She joined Penumbra in 2013 as a product manager and has played a significant role in building the company's vascular division and commercializing its thrombectomy products globally [2][3] - Narayan holds a B.S. in Electrical Engineering from Anna University, India, and an M.S. in Biomedical Engineering from the University of Southern California, focusing on Medical Device Commercialization [3] Company Overview - Penumbra, Inc. is a leading thrombectomy company focused on innovative technologies for medical conditions such as ischemic stroke and pulmonary embolism [4] - The company offers a broad portfolio, including computer-assisted vacuum thrombectomy (CAVT), aimed at improving patient outcomes and quality of life in over 100 countries [4]

Core Insights - AngioDynamics (ANGO) is experiencing growth driven by its NanoKnife product and a focus on cancer treatment markets, supported by a strong fourth-quarter fiscal 2025 performance and ongoing studies [1][6][10] - The company's shares have seen a slight decline of 0.3% year-to-date, contrasting with a 7% decline in the industry and an 8.8% increase in the S&P 500 [1][2] Company Performance - AngioDynamics has a market capitalization of $358.8 million and projects a 50% growth over the next year, with earnings surpassing the Zacks Consensus Estimate in the last four quarters, averaging a surprise of 72.58% [2][3] - The fourth-quarter fiscal 2025 results showed a narrower adjusted loss per share and revenues exceeding expectations, indicating strong execution across both operating segments [11] Product and Market Dynamics - The NanoKnife product, which received FDA clearance and Breakthrough Device Designation, generated total revenues of $24.5 million in fiscal 2025, with fourth-quarter revenues of $7.2 million reflecting growth in disposable sales despite softer capital placements [3][4] - Recurring disposable sales grew by 9.6% for the year, providing a reliable revenue stream to offset variability in system placements [3] Clinical and Product Development - AngioDynamics is advancing a broad pipeline of clinical studies, including the AMBITION trial for Auryon and the RECOVER-AV trial for AlphaVac, aimed at enhancing its market position [7][8] - The NanoKnife's PRESERVE prostate trial has met primary endpoints, paving the way for reimbursement catalysts starting in 2026 [8] Financial Outlook - The company anticipates gross margins in the range of 53.5% to 55.5% for fiscal 2026, with adjusted EBITDA projected between $3.0 million and $8.0 million [13] - However, there has been a negative estimate revision trend for fiscal 2026, with the consensus estimate for loss per share expanding from 6 cents to 30 cents [14]